{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T02:20:39Z","timestamp":1767666039690},"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2014,2,4]],"date-time":"2014-02-04T00:00:00Z","timestamp":1391472000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0088049","type":"journal-article","created":{"date-parts":[[2014,2,4]],"date-time":"2014-02-04T22:23:40Z","timestamp":1391552620000},"page":"e88049","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":19,"title":["Cardiometabolic Risks of Blonanserin and Perospirone in the Management of Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1371","volume":"9","author":[{"given":"Taro","family":"Kishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nakao","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,2,4]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"S Leucht","year":"2009","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","article-title":"A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia","volume":"166","author":"S Leucht","year":"2009","journal-title":"Am J Psychiatry"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","article-title":"Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis","volume":"123","author":"C Rummel-Kluge","year":"2010","journal-title":"Schizophr Res"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/schbul\/sbq042","article-title":"Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons","volume":"38","author":"C Rummel-Kluge","year":"2012","journal-title":"Schizophr Bull"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Kishi T, Matsuda Y, Nakamura H, Iwata N (2012) Blonanserin for schizophrenia: Systematic review and meta-analysis of double-blind, randomized, controlled trials. J Psychiatr Res.","DOI":"10.1016\/j.jpsychires.2012.10.011"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s40263-013-0085-7","article-title":"Efficacy and tolerability of perospirone in schizophrenia: a systematic review and meta-analysis of randomized controlled trials","volume":"27","author":"T Kishi","year":"2013","journal-title":"CNS Drugs"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"D Moher","year":"2009","journal-title":"BMJ"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"R DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"JP Higgins","year":"2003","journal-title":"BMJ"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2165\/00023210-200923070-00006","article-title":"The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study","volume":"23","author":"E Garcia","year":"2009","journal-title":"CNS Drugs"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/WNF.0b013e3181dcda50","article-title":"Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial","volume":"33","author":"J Yang","year":"2010","journal-title":"Clin Neuropharmacol"},{"key":"ref12","first-page":"2059Y2079","article-title":"Clinical evaluation of blonanserin for schizophrenia: a double-blind trial comparing blonanserin with haloperidol","volume":"10","author":"M Murasaki","year":"2007","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"ref13","first-page":"297","article-title":"Clinical evaluation of blonanserin for schizophrenia -A randomized study comparing blonanserin with riperidone-","volume":"11","author":"S Miura","year":"2008","journal-title":"Jpt J Clin Psychopharmacol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2165\/11202620-000000000-00000","article-title":"Blonanserin: a review of its use in the management of schizophrenia","volume":"24","author":"ED Deeks","year":"2010","journal-title":"CNS Drugs"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1254\/fpj.132.351","article-title":"[Pharmacological profiles and clinical effects of blonanserin (Lonasen) on schizophrenia]","volume":"132","author":"T Ishibashi","year":"2008","journal-title":"Nihon Yakurigaku Zasshi"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jpsychires.2012.10.011","article-title":"Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials","volume":"47","author":"T Kishi","year":"2013","journal-title":"J Psychiatr Res"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.4088\/JCP.v65n1114","article-title":"Effects of Changing From Typical to Atypical Antipsychptic Drugs on Subjective Sleep Quality in Patients With Schizophrenia in a Japanese Population","volume":"65","author":"H Yamashita","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.pnpbp.2012.09.010","article-title":"A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients","volume":"40","author":"Y Takekita","year":"2013","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1440-1819.2009.01947.x","article-title":"Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study","volume":"63","author":"G Okugawa","year":"2009","journal-title":"Psychiatry and Clinical Neurosciences"},{"key":"ref20","first-page":"207","article-title":"Clinical Ecaluation of a Serotonin-2 and Dopamine-2 Receptor Antagonist (SDA), Perospirone HCI on Schizophrenia -A comparative double-blind study with mosapramine HCI-","volume":"24","author":"Y Kudo","year":"1997","journal-title":"Clin Eval"},{"key":"ref21","first-page":"159","article-title":"Clinical Ecaluation of a New Antipsychotic, Perospirone HCI, on Schizophrenia -A comparative double-blind study with haloperidol-","volume":"24","author":"M Murasaki","year":"1997","journal-title":"Clin Eval"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00023210-200115040-00006","article-title":"\u201cPerospirone\u201d","volume":"15","author":"S Onrust","year":"2001","journal-title":"CNS Drugs"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sj.mp.4002066","article-title":"Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles","volume":"13","author":"H Nasrallah","year":"2008","journal-title":"Mol Psychiatry"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/j.2051-5545.2009.tb00199.x","article-title":"Metabolic syndrome in people with schizophrenia: a review","volume":"8","author":"M DeHert","year":"2009","journal-title":"World Psychiatry"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.molmed.2010.10.010","article-title":"Antipsychotic drugs and obesity","volume":"17","author":"CU Correll","year":"2011","journal-title":"Trends Mol Med"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents","volume":"302","author":"CU Correll","year":"2009","journal-title":"JAMA"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0088049","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T09:32:32Z","timestamp":1565170352000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0088049"}},"subtitle":[],"editor":[{"given":"Kenji","family":"Hashimoto","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,2,4]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,2,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0088049","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,4]]}}}